Last update: May 11, 2019
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Central action alpha-1 adrenergic blocker with indications similar to clonidine, used in the treatment of hypertension and attention deficit hyperactivity disorder.
Oral administration once a day.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight, low protein binding and prolonged half-life) make it likely that it would pass into breast milk in amounts which could be significant.
It can reduce prolactin levels (Hauger 1981), but when lactation is well established, milk production does not depend so much on prolactin levels.
Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug may be used (Anderson 2018, Schaefer 2007 p685), especially during the neonatal period and/or in case of premature infants.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM